We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Policy & Law > Global Healthcare > Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have
BusinessGlobal HealthcareNews

Doctors Without Borders VS Johnson and Johnson Who Will Not Donate Licenses for HIV/AIDS Drugs as Others Have

BarbaraDuck
BarbaraDuck
Share
3 Min Read
SHARE

Johnson and Johnson refuses to join the Medicines Patent Pool as others have done so generic drugs can be made in developing countries. As you can read through here, they do get some small payments from licensing the drugs and the other countries might just do a copy cat anyway.Johnson and Johnson refuses to join the Medicines Patent Pool as others have done so generic drugs can be made in developing countries. As you can read through here, they do get some small payments from licensing the drugs and the other countries might just do a copy cat anyway.image

Johnson and Johnson said there was no urgency here but that does not seem to be the case if you just read the news. In saying no to the Medicines Patent Pool, Johnson & Johnson has made a conscious, willful decision to turn its back on people living with HIV and there’s even one license held by the NIH that is useless as it is a partial patent for darunavir so without all being members not much gets done. Here’s a video from South Africa with one doctor talking about their need for some of the J and J drugs. BD

aram>mbed>bject>iv>”;” alt=””>
HIV-AIDS Drugs

At the end of 2011, there were about 15 million people who needed HIV/AIDS treatment, but only about 6 million people received proper care. Part of the reason is that it is costly to treat HIV/AIDS and most people living with HIV/AIDS are poor and live in countries that simply don’t have the means to provide treatment to everyone who needs it.

Although the cost of standard HIV/AIDS treatments have gone down significantly over the years, there are still certain specialized medicines or specialized combinations of medicines that are really expensive. One idea that humanity drew up to reduce the costs of these expensive treatments is something called the Medicines Patent Pool.

The idea is pretty basic. Patent holders from western pharmaceutical giants voluntarily give up their patents for expensive AIDS drugs. A World Health Organization-certified drug manufacturer in say, in India or Kenya, produces cheap generic versions of these expensive drugs for the exclusive sale in the developing world. They pay a royalty to the original western patent holder, but nothing too onerous.

The western pharma giant gets paid (and gains access to new markets). HIV patients in the developing world get their medicines cheap. Everyone wins, right? Not so, says Johnson & Johnson which is refusing to turn over three of its patents to the pool.

http://www.undispatch.com/doctors-without-borders-v-johnson-johnson

Technorati Tags: HIV,AIDS,Johson and Johnson,drugs,patents,generic drugs,pharma,royalties


More Read

Physician Online Reputations: What Role for Hospitals?
Investor red flags- always logical?
Boston Marathon vs Terror: Boston Wins
How to Deal With Online Patient Complaints
Temporary Health Plans With Low Benefits Continue to Grow

TAGGED:AIDSHIVJohnson & Johnsonpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

Flat editorial illustration: Clinical-trial operations editorial illustration combining healthcare and technology: country-specif
Clinical Study Operations Across Eastern European Research Markets
Health
October 31, 2026
Flat editorial illustration: A health-editorial scene of a first pain-management visit, bringing together attentive consultation,
What to Expect at Your First Pain Management Appointment
Therapies Wellness
October 29, 2026
Flat editorial illustration: The core relationship is medication-only coverage versus coverage for a supervised clinical program.
Medical Weight Loss as a Workplace Benefit: The Questions I Would Want Asked
Weight Loss Wellness
October 29, 2026
Common Questions About Tirzepatide and Medical Monitoring -- AI-generated illustration
Common Questions About Tirzepatide and Medical Monitoring
Health
October 26, 2026

You Might also Like

Medicare Prescription Drug Abuse

October 11, 2011

Three Ways a Hospital Can Use LinkedIn

March 2, 2014
NewsPolicy & Law

Bad Weather Conditions Can Cause Painful Injuries

February 11, 2024
Revenue Cycle Dollars
BusinessFinanceHospital Administration

Hospital-Based Physicians and Revenue Cycle Management

September 7, 2014
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?